Results 31 to 40 of about 18,836 (198)

Acute kidney injury:an unusual complication of posaconazole use [PDF]

open access: yes, 2018
Triazole antifungals are useful in the treatment of Aspergillus disease and these drugs have side effects which clinicians should be aware of. Posaconazole is an orally administered second-generation triazole antifungal agent which inhibits lanosterol 14-
Bongomin, Felix   +7 more
core   +1 more source

Effects of Posaconazole on Tacrolimus Population Pharmacokinetics and Initial Dose in Children With Crohn’s Disease Undergoing Hematopoietic Stem Cell Transplantation

open access: yesFrontiers in Pharmacology, 2022
The present study explored the effects of posaconazole on tacrolimus population pharmacokinetics (PPK) in children with Crohn’s disease (CD) undergoing hematopoietic stem cell transplantation (HSCT).
Xiao Chen   +8 more
doaj   +1 more source

Posaconazole: A Review of Drug Interactions with HIV Antiretroviral Agents

open access: yesPharmacy, 2014
The purpose of this review is to examine the literature for reports of clinically significant interactions noted amongst HIV antiretroviral medications when coadministered with posaconazole.
Mara Poulakos, Amy Henneman, Simon Leung
doaj   +1 more source

Azole-Resistant Aspergillosis: An Emerging Diagnostic and Therapeutic Challenge in Paediatrics. [PDF]

open access: yesMycoses
ABSTRACT Introduction Invasive aspergillosis (IA) represents one of the most frequent invasive fungal infections in paediatric patients with risk factors. An increase in cases of azole‐resistant IA has been reported in adult patients. The aim of this study is to present a series of 11 cases of paediatric patients with this pathology.
Mendoza-Palomar N   +14 more
europepmc   +2 more sources

Rapid and sensitive determination of posaconazole in patient plasma by capillary electrophoresis with field-amplified sample stacking

open access: yes, 2014
The high morbidity and mortality associated with invasive fungal infections have increased the importance of improving treatment efficacy. Posaconazole is a novel agent with strong antifungal activity and low toxicity.
Liao, Hsiao-Wei;Lin, Shu-Wen;Wu, Un-In;Kuo, Ching-Hua   +1 more
core   +1 more source

Invasive fungal infection following venetoclax and posaconazole co-administration

open access: yes, 2023
The co-administration of venetoclax, a BCL-2 inhibitor, with a mould-active azole, such a posaconazole, has potential to both prevent invasive fungal infection (IFI) and reduce the required treatment dose, and cost, of venetoclax. Posaconazole drug-level
Reynolds, G   +3 more
core   +1 more source

Posaconazole-Induced Adrenal Insufficiency in a Case of Chronic Myelomonocytic Leukemia

open access: yesCase Reports in Endocrinology, 2018
Introduction. Posaconazole is an azole used in treatment and prophylaxis of a broad spectrum of fungal infections. Antifungals such as ketoconazole have been shown to cause primary adrenal insufficiency (AI) as a result of direct inhibition on the ...
Ann Miller   +3 more
doaj   +1 more source

Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience

open access: yesHaematologica, 2012
Background Posaconazole is effective as primary antifungal prophylaxis of invasive fungal diseases in patients with acute myeloid leukemia.Design and Methods The impact of primary antifungal prophylaxis administered during front-line chemotherapy for ...
Corrado Girmenia   +14 more
doaj   +1 more source

The tablet formulation of posaconazole: clinical pharmacology and the use in patients with hematologic malignancies [PDF]

open access: yesКлиническая микробиология и антимикробная химиотерапия, 2020
Posaconazole is a broad-spectrum triazole antifungal agent with potent activity against various fungi, including yeast and molds, including Mucorales, what makes a key difference with itraconazole and voriconazole.
Veselov A.V.
doaj   +1 more source

Posaconazole

open access: yesDrugs in R & D, 2003
Posaconazole [SCH 56592, SPRIAFIL, Noxafil] is an orally active triazole derivative that is in phase III trials with the Schering-Plough Research Institute (SPRI) in the US for the treatment of serious opportunistic fungal infections, including aspergillosis, candidiasis, coccidioidomycosis and fusariosis.
openaire   +2 more sources

Home - About - Disclaimer - Privacy